|
Broder GM, Pritchard J, Berthold F, Hedborg F
|
Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.
|
J Clin Oncol
|
1993
|
11
|
8
|
1466–77
|
1450
|
55.7
|
|
Kaghad M,Bonnet H, Yang A, Caput D
|
Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers
|
Cell
|
1997
|
90
|
4
|
809–19
|
1403
|
63.7
|
|
Broder GM
|
Neuroblastoma: Biological insights into a clinical enigma
|
Nat Rec Cancer
|
2003
|
3
|
3
|
203–16
|
1328
|
83.0
|
|
Matthay KK, Villablanca JG, Seeger RC, Reynolds
|
Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid
|
N Engl J Med
|
1999
|
341
|
16
|
1165–73
|
1246
|
62.3
|
|
Maris JM, Hogarty MD, Bagatell R, Cohn SL
|
Neuroblastoma
|
Lancet
|
2010
|
369
|
9579
|
2106–20
|
1153
|
96.1
|
|
Maris JM
|
Recent Advances in Neuroblastoma
|
N Engl J Med
|
2010
|
362
|
23
|
2202–11
|
792
|
88.0
|
|
Yu AL, Gilman AL, Ozkaynak MF, Sondel PM
|
Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
|
N Engl J Med
|
2010
|
363
|
14
|
1324–34
|
707
|
78.5
|
|
Mosse YP, Laudenslager M, Longo L, Maris JM
|
Identification of ALK as a major familial neuroblastoma predisposition gene
|
Nature
|
2008
|
455
|
7215
|
930–5
|
704
|
64.0
|
|
Shimada H, Chatten J, Newton WA, Misugi K
|
Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas
|
J Natl Cancer Inst
|
1984
|
73
|
2
|
405–16
|
686
|
19.6
|
|
Pule M, Savoldo B, Myers GD, Brenner MK
|
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
|
Nat Med
|
2008
|
14
|
11
|
1264–70
|
674
|
61.3
|
